1. Home
  2. GBIO vs VIGL Comparison

GBIO vs VIGL Comparison

Compare GBIO & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • VIGL
  • Stock Information
  • Founded
  • GBIO 2016
  • VIGL 2020
  • Country
  • GBIO United States
  • VIGL United States
  • Employees
  • GBIO N/A
  • VIGL N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • VIGL Health Care
  • Exchange
  • GBIO Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • GBIO 29.2M
  • VIGL 134.9M
  • IPO Year
  • GBIO 2020
  • VIGL 2022
  • Fundamental
  • Price
  • GBIO $0.32
  • VIGL $7.96
  • Analyst Decision
  • GBIO Strong Buy
  • VIGL Buy
  • Analyst Count
  • GBIO 4
  • VIGL 7
  • Target Price
  • GBIO $7.33
  • VIGL $8.00
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • VIGL 1.5M
  • Earning Date
  • GBIO 08-06-2025
  • VIGL 08-12-2025
  • Dividend Yield
  • GBIO N/A
  • VIGL N/A
  • EPS Growth
  • GBIO N/A
  • VIGL N/A
  • EPS
  • GBIO N/A
  • VIGL N/A
  • Revenue
  • GBIO $24,556,000.00
  • VIGL N/A
  • Revenue This Year
  • GBIO N/A
  • VIGL N/A
  • Revenue Next Year
  • GBIO N/A
  • VIGL N/A
  • P/E Ratio
  • GBIO N/A
  • VIGL N/A
  • Revenue Growth
  • GBIO 146.47
  • VIGL N/A
  • 52 Week Low
  • GBIO $0.30
  • VIGL $1.31
  • 52 Week High
  • GBIO $3.65
  • VIGL $7.96
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 43.92
  • VIGL 88.44
  • Support Level
  • GBIO $0.35
  • VIGL $7.86
  • Resistance Level
  • GBIO $0.38
  • VIGL $7.90
  • Average True Range (ATR)
  • GBIO 0.03
  • VIGL 0.03
  • MACD
  • GBIO -0.00
  • VIGL -0.20
  • Stochastic Oscillator
  • GBIO 3.33
  • VIGL 91.67

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

Share on Social Networks: